If you typed Visionware Clinical into a search box, you are probably building a CRO shortlist. This article uses only what Visionware Clinical publishes (visionwareclinical.com · visionwareclinical.com/services · visionwareclinical.com/about-us) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.
What Visionware Clinical publishes
Visionware Clinical is a Sydney-area (Mosman, NSW) contract research organisation that calls itself an emerging CRO in Australia and New Zealand specialising in medical devices. Its services page covers consulting, data gathering, medical writing, clinical trials and regulatory work. It says it will help design and conduct first-in-human, feasibility and pivotal trials, set up paper or electronic data capture, and support ARTG registration with the TGA. It also advises on Australia's R&D tax incentive and on setting up a local entity. Dina Peleg Kowarski is CEO and Director of Clinical Operations, with more than 15 years in clinical trials. We found no named sponsor or study on its site.
Visionware Clinical vs bioaccess®
| Dimension | Visionware Clinical | bioaccess® |
|---|---|---|
| Core focus | Boutique Australian medical-device CRO | First-in-human and early feasibility studies for medical devices |
| Geography | Australia and New Zealand | Latin America, since 2010 |
| Device FIH track record | No named device first-in-human study found on the public pages reviewed | Published case studies on bioaccessla.com |
| After the trial | ARTG registration support with the TGA and post-market clinical trials, per its services page | Live multi-country sanitary registration and in-country holder service |
Where each one fits
If you want a small device-only team for a first Australian feasibility study, with ARTG support afterwards, Visionware publishes that offer.
If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO on your list, including Visionware Clinical, for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.
Australia sells real country features: the CTN scheme, English-language ethics and, for eligible companies, the R&D tax incentive. Those are country features, not Visionware Clinical features. The country math is on bioaccess® vs Australia, and the established Australian device EFS boutique is covered in Mobius Medical vs bioaccess®.
Ready to compare a proposal? Request a first-in-human study proposal.
Competitor facts from the Visionware Clinical public pages linked above and public announcements, reviewed for bioaccess® competitive research (Aug 2026–Nov 2026). Claims are theirs. No invented sponsors, prices or contacts.